MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
10.22
+0.21 (2.14%)
At close: Nov 11, 2026, 4:00 PM EST
10.22
0.00 (-0.04%)
Pre-market: Nov 12, 2026, 6:35 AM EST
MiNK Therapeutics Employees
MiNK Therapeutics had 15 employees as of December 31, 2025. The number of employees decreased by 8 or 34.78% compared to the previous year. That makes MiNK Therapeutics the 39,154th largest employer in the world and 5,713th in the United States.
Employees
15
Change (1Y)
-8
Growth (1Y)
-34.78%
Revenue / Employee
n/a
Profits / Employee
-$757,359
Market Cap
52.17M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | -8 | -34.78% |
| Dec 31, 2024 | 23 | -8 | -25.81% |
| Dec 31, 2023 | 31 | -6 | -16.22% |
| Dec 31, 2022 | 37 | 4 | 12.12% |
| Dec 31, 2021 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Oncolytics Biotech | 29 |
| Boundless Bio | 28 |
| Actinium Pharmaceuticals | 27 |
| iBio, Inc. | 23 |
| RenovoRx | 17 |
| Rein Therapeutics | 10 |
INKT News
- 22 hours ago - MiNK Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 22 hours ago - MiNK Therapeutics Earnings release: Q3 2026 - Filings
- 23 hours ago - MiNK Therapeutics reports Q3 EPS (50c), consensus (66c) - TheFly
- 23 hours ago - MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies - GlobeNewsWire
- 5 days ago - MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) - GlobeNewsWire
- 8 days ago - MiNK Therapeutics assumed with a Buy at H.C. Wainwright - TheFly
- 9 days ago - MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy - GlobeNewsWire
- 22 days ago - MiNK Therapeutics price target raised to $50 from $43 at B. Riley - TheFly